← Back to Search

Radiotracer

Total-body PET Imaging for Cancer

N/A
Waitlist Available
Led By Lorenzo Nardo, MD
Research Sponsored by University of California, Davis
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Men >18 years old with suspected prostate cancer metastasis who are candidates for initial definitive therapy or with suspected recurrence based on elevated serum PSA level
Persons > 18 years old suspicious for or diagnosed with somatostatin receptor positive neuroendocrine tumors (NETs)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up one study imaging visit lasting up to 10 hours
Awards & highlights

Study Summary

This trial is testing new ways to improve the EXPLORER, the world's first total-body PET/CT scanner, by using it with three different imaging agents.

Who is the study for?
This trial is for adults with certain types of cancer: prostate, neuroendocrine tumors, or breast cancer. Participants must have had a previous imaging study within the last 4 months that suggests metastatic disease. Men over 18 suspected of having prostate cancer recurrence based on PSA levels can also join.Check my eligibility
What is being tested?
The study tests new ways to use the EXPLORER total-body PET/CT scanner with FDA-approved imaging agents (18F-PSMA for prostate cancer, 68Ga DOTATATE for neuroendocrine tumors, and 18F-FES for breast cancer) to improve diagnostic accuracy.See study design
What are the potential side effects?
Since this trial focuses on imaging techniques rather than medication or invasive procedures, side effects are minimal but may include discomfort from lying still during scanning and exposure to radiation typical of PET/CT scans.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am a man over 18 with suspected prostate cancer spread or recurrence, indicated by high PSA levels.
Select...
I am over 18 and have or might have a neuroendocrine tumor that is somatostatin receptor positive.
Select...
I am over 18 and have breast cancer that has come back or spread.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~one study imaging visit lasting up to 10 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and one study imaging visit lasting up to 10 hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
measure radiotracer avidity

Trial Design

1Treatment groups
Experimental Treatment
Group I: Total-body PET scanExperimental Treatment1 Intervention
All participants will receive a dynamic PET scan for up to 90 minutes. This will be followed by two 30 minutes static PET scans at 3 hours +/-20 minutes and 6 hours +/-20 minutes post injection. Subjects injected with 18F-PSMA or 18F-FES will receive a 40 minute scan at 9 hours +/-20 minutes post injection.

Find a Location

Who is running the clinical trial?

University of California, DavisLead Sponsor
908 Previous Clinical Trials
4,704,106 Total Patients Enrolled
15 Trials studying Breast Cancer
1,342,972 Patients Enrolled for Breast Cancer
Lantheus Medical ImagingIndustry Sponsor
55 Previous Clinical Trials
4,332,650 Total Patients Enrolled
2 Trials studying Breast Cancer
255 Patients Enrolled for Breast Cancer
Lorenzo Nardo, MDPrincipal InvestigatorUniversity of California, Davis
3 Previous Clinical Trials
278 Total Patients Enrolled

Media Library

18F-FES (Radiotracer) Clinical Trial Eligibility Overview. Trial Name: NCT05160480 — N/A
Breast Cancer Research Study Groups: Total-body PET scan
Breast Cancer Clinical Trial 2023: 18F-FES Highlights & Side Effects. Trial Name: NCT05160480 — N/A
18F-FES (Radiotracer) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05160480 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is enrollment still open for this experiment?

"Sadly, based on the data posted on clinicaltrials.gov this study is not presently searching for participants; it was originally listed on December 1st 2022 and last modified September 29th 2022. Although no longer enrolling candidates, 2387 other clinical trials are currently recruiting patients at the moment."

Answered by AI
~6 spots leftby Sep 2024